Applicant, as named in the Orange Book

Eli Lilly And Co

Next listed expiry: Verzenio on 28 Sep 2031. 12 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Verzenio · 4 strengths abemaciclib	abemaciclib	208716	28 Sep 2031	patent
Olumiant · 3 strengths baricitinib	baricitinib	207924	30 Nov 2032	patent, carve-out possible
Foundayo · 6 strengths orforglipron calcium	orforglipron calcium	220934	26 Sep 2037	patent
Retevmo · 2 strengths selpercatinib	selpercatinib	213246	10 Apr 2039	patent
Retevmo · 4 strengths selpercatinib	selpercatinib	218160	10 Apr 2039	patent
Inluriyo imlunestrant tosylate	imlunestrant tosylate	218881	11 Jul 2039	patent
Zepbound · 12 strengths tirzepatide	tirzepatide	217806	22 Jul 2039	patent, carve-out possible
Zepbound (Autoinjector) · 6 strengths tirzepatide	tirzepatide	217806	22 Jul 2039	patent, carve-out possible
Zepbound Kwikpen · 6 strengths tirzepatide	tirzepatide	217806	22 Jul 2039	patent, carve-out possible
Mounjaro · 12 strengths tirzepatide	tirzepatide	215866	30 Dec 2041	patent, carve-out possible
Mounjaro (Autoinjector) · 6 strengths tirzepatide	tirzepatide	215866	30 Dec 2041	patent, carve-out possible
Mounjaro Kwikpen · 6 strengths tirzepatide	tirzepatide	215866	30 Dec 2041	patent, carve-out possible

25 Oct 2026Verzenio · Generic tentatively approved 6 Nov 2025
24 Oct 2026Zepbound (Autoinjector) · Exclusivity expires within 90 days NP8 Nov 2026
24 Oct 2026Zepbound (Autoinjector) · Exclusivity expires within 90 days NP8 Nov 2026
24 Oct 2026Zepbound (Autoinjector) · Exclusivity expires within 90 days NP8 Nov 2026
24 Oct 2026Zepbound (Autoinjector) · Exclusivity expires within 90 days NP8 Nov 2026
24 Oct 2026Zepbound (Autoinjector) · Exclusivity expires within 90 days NP8 Nov 2026
24 Oct 2026Zepbound (Autoinjector) · Exclusivity expires within 90 days NP8 Nov 2026
24 Oct 2026Axiron · Enters 12-month window basis: patent, carve-out possible27 Sep 2027